Gastroparesis Drug Enters Phase 3 Clinical Trials
Adults with gastroparesis may soon see progress as new clinical trials prepare to launch globally in 2027.
Updated on Oct. 21, 2026 in Diabetes
Live Poll
Do you believe pharmaceutical companies are making enough progress in developing effective long-term treatments for chronic conditions?
Dr. Falk Pharma and Renexxion have reached alignment with the FDA and EMA to begin a Phase 3 clinical trial program for the drug naronapride. The upcoming studies will evaluate the treatment for adults suffering from diabetic and idiopathic gastroparesis.
Why it matters
Gastroparesis is a chronic condition with limited therapeutic options, making new clinical research critical for those living with the disorder. By coordinating with global regulators, the companies aim to streamline development and address this significant unmet medical need.
The planned Phase 3 program follows the MOVE-IT Phase 2b trial, which evaluated naronapride in adults with diabetic and idiopathic gastroparesis. Efficacy and safety outcomes from the upcoming global Phase 3 trials have yet to be established.
The players
Dr. Falk Pharma
A Germany-based pharmaceutical company focused on gastroenterology and hepatology therapies.
Renexxion
A biopharmaceutical company specializing in the development of treatments for gastrointestinal disorders.
FDA
The U.S. agency responsible for regulating food, drugs, and medical devices to ensure public health safety.
EMA
The European Union agency tasked with the scientific evaluation, supervision, and safety monitoring of medicines.
The details
The Phase 3 program will utilize the ANMS-GCSI-DD tool to measure primary and key secondary endpoints in patients. Regulators have approved the conduction of studies required for a New Drug Application in parallel with the Phase 3 clinical trials to expedite the timeline. The trials will specifically target the mechanisms of diabetic and idiopathic gastroparesis to address gaps in current patient care.
Timeline
October 21, 2026: Companies announced regulatory alignment for the Phase 3 program.
First half of 2027: Planned initiation of the global Phase 3 clinical trials.
Health Landscape
The development of naronapride follows a standardized regulatory path designed to satisfy New Drug Application requirements through coordinated global testing. This approach aims to accelerate the transition from Phase 2b findings to potential future clinical availability.
This news indicates progress in pipeline research for those managing gastroparesis, though it does not yet change current treatment protocols. Patients interested in these developments should discuss ongoing research progress and clinical trial eligibility with their gastroenterologist.
The takeaway
The advancement of naronapride into Phase 3 trials represents a major step toward expanding options for gastroparesis management. Patients should continue to monitor their symptoms closely and consult their physician regarding updates in gastrointestinal care.
Further reading
Learn more about the latest research and management strategies for patients at Diabetes.
More information
For more on the company's research, visit Dr. Falk Pharma corporate information.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you believe pharmaceutical companies are making enough progress in developing effective long-term treatments for chronic conditions?
